17β-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.

ABSTRACT:

Background

Premenopausal women diagnosed with estrogen receptor (ER)-positive breast cancer are prescribed 5-10 years of tamoxifen therapy to prevent or delay a recurrence. The enzymes 17β-hydroxysteroid dehydrogenase 1 and 2 (HSD17B1 and HSD17B2, respectively) regulate the relative concentrations of estrogen metabolites and may modify tamoxifen effectiveness. We evaluated the prognostic and predictive value of HSD17B1 and HSD17B2 expression in breast tumors.

Methods

We identified a cohort of premenopausal breast cancer patients from the Danish Breast Cancer Group database (2002-2011) and stratified on ER status and receipt of tamoxifen (4600 ER+/TAM + and 1359 ER-/TAM-). Biomarkers HSD17B1 and HSD17B2 were assayed by immunohistochemistry. We used Cox proportional hazards re

SUBMITTER: Collin LJ 

PROVIDER: S-EPMC12857100 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature